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The  GLI1  oncogene  and  p53  tumor  suppressor  gene  function  in an inhibitory  loop  that  controls  stem  cell
and tumor  cell numbers.  Since  GLI1  and  p53 both  interact  with  the  coactivator  TATA Binding  Protein
Associated  Factor  9  (TAF9),  we  hypothesized  that  competition  between  these  transcription  factors  for
TAF9 in  cancer  cells  may  contribute  to the  inhibitory  loop  and  directly  affect  GLI1  function  and  cellular
phenotype.  We  showed  that  TAF9  interacts  with  the  oncogenic  GLI family  members  GLI1 and  GLI2  but
not  GLI3  in cell-free  pull-down  assays  and  with GLI1  in rhabdomyosarcoma  and  osteosarcoma  cell  lines.
Removal  of the TAF9-binding  acidic  alpha  helical  transactivation  domain  of  GLI1  produced  a  signiﬁcant
reduction  in  the ability  of GLI1 to transform  cells.  We  then  introduced  a point  mutation  into  GLI1  (L1052I)
that  eliminates  TAF9  binding  and  a point  mutation  into  GLI3  (I1510L)  that  establishes  binding.  Wild-type
and  mutant  GLI proteins  that bind  TAF9  showed  enhanced  transactivating  and  cell  transforming  activity
compared  with  those  that  did  not.  Therefore,  GLI-TAF9  binding  appears  important  for  oncogenic  activity.
We  then  determined  whether  wild-type  p53 down-regulates  GLI  function  by sequestering  TAF9.  We
showed  that p53  binds  TAF9  with  greater  afﬁnity  than  does  GLI1  and  that  co-expression  of p53  with  GLI1
or  GLI2  down-regulated  GLI-induced  transactivation,  which  could  be abrogated  using  mutant  forms  of
GLI1 or  p53.  This  suggests  that  p53 sequesters  TAF9  from  GLI1,  which  may  contribute  to  inhibition  of
GLI1  activity  by  p53  and  potentially  impact  therapeutic  success  of  agents  targeting  GLI-TAF9  interactions
in  cancer.
© 2015  The  Authors.  Published  by  Elsevier  B.V.  This  is  an  open  access  article  under the  CC  BY-NC-ND. Introduction
GLI family zinc ﬁnger transcription factors (GLI1, GLI2, and GLI3)
ediate Hedgehog signaling during vertebrate development [1].
LI1 and GLI2 expression have been associated with a wide variety
f human cancers and both transform rodent cells in tissue culture
2–4]. In contrast, fewer examples of GLI3 expression in human can-
er have been described [5,6]. Activation of GLI family transcription
actors in human cancers occurs by several mechanisms, includ-
ng constitutive activation of canonical Hedgehog signaling [4] and
on-canonical direct activation of GLII or GLI2 without involvement
f upstream Hedgehog signaling [7,8]. Therefore, although clini-
Abbreviations: TAF9, TATA binding protein associated factor 9; TAD1, acidic
lpha helical transactivation domain.
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cal trials are underway using Smo  inhibitors [9–11], targeting the
downstream GLI transcription factors may  be more appealing [12].
GLI proteins share a highly conserved zinc ﬁnger DNA bind-
ing domain and binding speciﬁcity, however their transactivating
properties differ based on differences in an amino terminal tran-
scription inhibitory domain, a carboxy terminal acidic alpha helical
transactivation domain (TAD1), and whether the protein undergoes
cleavage to remove TAD1 [13–17]. Transactivation represents the
presumed mechanism for their oncogenic activity. Therefore, we
initiated studies to determine functional differences among TAD1s
of different GLI family proteins.
GLI1, GLI2, and GLI3 TAD1s show sequence homology to the
VP-16 and p53 acidic alpha helical transactivation domains [16].
The VP-16, p53, GLI1 and GLI2 domains bind the coactivator TATA
Binding Protein Associated Factor 9 (TAF9) through a conserved
consensus recognition motif, and amino acids directly interacting
with TAF9 have been identiﬁed [12,19–21]. The interaction of GLI1
and GLI2 with TAF9 is important in small cell lung cancer and a spe-
ciﬁc inhibitor of the GLI-TAF9 interaction, FN1-8 has recently been
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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eveloped that suppresses tumor growth in vivo [12]. In addition, a
LI1-p53 inhibitory loop plays a role in inactivation of the HH sig-
aling pathway in genotoxic stress [17], and controls neural stem
ell and tumor cell numbers [18]. However, a role for TAF9 in this
nhibitory loop has not been described. Therefore, we tested the
mpact of p53 on GLI-TAF9 interactions in cancer. Understanding
echanisms that regulate GLI-TAF9 interactions may  be important
or designing successful treatment strategies that target GLI-TAF9
nteractions.
Here, we demonstrate that TAD1s of GLI1 and GLI2 interact
ith TAF9; the interaction with TAF9 enhances transactivation and
ransformation by GLI family transcription factors; p53 interacts
ith TAF9 with higher afﬁnity than GLI1; and p53 squelches GLI1
nd GLI2 activity by sequestrating TAF9. Sequestration of TAF9
ontributes to inhibition of GLI1 activity by p53 and may impact
herapeutic success of agents targeting GLI-TAF9 interactions in
ancer.
. Materials and methods
.1. Constructs
.1.1. Constructs used for transcriptional activity assays
pCMV-GLI1 was prepared by inserting GLI1 (amino acids 1-1106)
obtained from Dr. Kinzler, Johns Hopkins University, Baltimore,
D)  [22] into pcDNA3 (Invitrogen, Carlsbad, CA). pM-GLI1 was  pre-
ared by inserting GLI1 (amino acids 78 - 1106) into the pM vector
Clontech, Mountain View, CA) [16]. pVP-16-GLI1 was prepared by
nserting GLI1 (amino acids 78-1106) into pVP-16 (Clontech, Moun-
ain View, CA).
pM-GLI1TAD1 (amino acids 879–1106) was prepared by insert-
ng a PCR ampliﬁed GLI1 fragment into the pM vector. PCR primers
re shown in the supporting information section. The pM-GLI1TAD1
1052I mutant construct was prepared from pM-GLI1TAD1 using a
ite-directed mutagenesis kit (Stratagene, LaJolla, CA). Primers for
ite directed mutagenesis are shown in the supporting information
ection. pM-GLI2TAD1 and pM-GLI3TAD1 were prepared by insert-
ng GLI2 TAD1 (amino acids 1090 - 1228) or GLI3 TAD1 (amino acids
397-1549) into the pM vector. pM-GLI3TAD1 I1510L was prepared
rom pM-GLI3TAD1 using a site-directed mutagenesis kit. Primers
or site directed mutagenesis and construct preparation are shown
n the supporting information section.
The pGL3b/8Xgli-lc-luc reporter construct was obtained from
r. Beachy (Stanford University, Stanford, CA) [23]. A wild-type
53 expression construct, pRc/CMVhp53, a p53 22–23 mutant
onstruct, and the pBP100-GL2 reporter construct, containing a
53-binding site in the mouse Mdm2  core promoter, were obtained
rom Dr. Levine (Institute for Advanced Study, Princeton, NJ) [24].
53 R175H and R248W mutant constructs were obtained from Dr.
ogelstein (Johns Hopkins University, Baltimore, MD)  [25]. pCMV-
LI2 was obtained from Dr. Markovitz (University of Michigan, Ann
rbor, MI)  [26].
.1.2. Constructs used for cell-free pull-down assays
TAF9 cDNA was PCR ampliﬁed and inserted into pGEX-5T-2 (Bio-
ad, Hercules, CA). Primers for cDNA ampliﬁcation are shown in the
upporting information section. Consensus TAF9 binding domains
f GLI1 (amino acids 912–1070), GLI2 (amino acids 1090–1228),
nd GLI3 (amino acids 1397–1549) were PCR ampliﬁed and ligated
nto the pET21(+) protein expression vector (Novagen, Madison,
I). Primers for construct preparation are shown in the supportingnformation section. pET21(+)-GLI1TAD1 L1052I and pET21(+)-
LI3TAD1 I1510L were prepared using a site-directed mutagenesis
it. Site-directed mutagenesis primers are the same for pM or pET
ectors. A p53 protein expression construct, pRSET(A)-p53, wasair 34 (2015) 9–17
obtained from Dr. Nyborg (Colorado State University, Fort Collins,
CO) [27].
2.1.3. pLTR constructs used for transformation assays
pLTR-GLI1 was obtained from Dr. Kinzler (Johns Hopkins Uni-
versity, Baltimore, MD)  [3]. pLTR-GLI1853-1106 was prepared by
deleting GLI1 amino acids 853 - 1106 using PCR, shown in the sup-
porting information section. pLTR-GLI1 L1052I was prepared from
pM-GLI1 L1052I. pLTR-GLI3 was prepared from pDZ77, which was
obtained from Dr. Zarkower (University of Minnesota, Minneapolis,
MN)  [28].
2.2. Transcriptional activity assays
HeLa cells (American Type Culture Collection (ATCC) 2-CCL,
Manassas, VA) were co-transfected using Lipofectamine 2000
reagent (Invitrogen, Carlsbad, CA) with 0–2000 ng of effector plas-
mid, 200–600 ng of either the pG5CAT (Promega, Madison, WI),
pG5Luc (Promega, Madison, WI), pGL3b/8XGli-lc-luc, or pBP100-
GL2 reporter construct, and either 10 ng of Renilla control reporter
(Promega, Madison, WI)  or 400 ng of pSV40-GAL control reporter
(Promega, Madison, WI). Cell lysates were prepared 24–48 h after
transfection. Luciferase activity was measured with a luminometer
(Lumat LB9501, Berthold, Oak Ridge, TN) and was normalized using
a Renilla control reporter (Promega, Madison, WI). CAT assays were
performed by incubating lysates with 14C-chloramphenicol and n-
Butyryl CoA. -galactosidase activity was  used to normalize the CAT
activity in the lysate. The experiments were performed at least in
triplicate and results expressed as a mean with standard deviation.
Statistical signiﬁcance was  assessed using the Student’s t test.
2.3. Cell-free protein–protien pull-down assays
GST- or GST-TAF9-glutathione sepharose beads (BioRad, Her-
cules, CA) were incubated with protein expressed in bacteria from
pET21(+)-GLI1TAD1, pET21(+)-GLI2TAD1, pET21(+)-GLI3TAD1,
pET21(+)-GLI1TAD1 L1052I, pET21(+)-GLI3TAD1 I1510L, and/or
pRSET(A)-p53 in 1X binding buffer (Tris-HCl, pH 7.5, 50 mM NaCl,
0.005% NP-40, and 10% glycerol) for 1 h at 4 ◦C. The beads were
washed, and proteins were detected by Western blot analysis using
anti-histidine tag antibody (Novagen, Madison, WI)  or anti-T7
antibody (Novagen, Madison, WI).
2.4. Western blot analysis
50–100 g of protein was  separated by SDS-PAGE electrophore-
sis, and transferred onto PVDF membranes (Millipore, Billerica,
MA). Polyclonal antibodies against Flag (Sigma, St. Louis, MO), T7
or histidine tags were used to detect the proteins, which were then
visualized using a chemiluminescence kit (Pierce Inc., Rockford, IL).
Densitometric quantitation of the protein levels was  determined
using an Artixscan scanner (Microtek, Fontana, CA) and Silverfast
software (Lasersoft Imaging, Inc., Sarasota, FL).
2.5. Co-immunoprecipitation assays
Lysate from RMS-13 cells (ATCC CRL-2061, Manassas, VA) was
pre-cleared by control IgG and protein G-Plus agarose (Santa Cruz
Biotech, Santa Cruz, CA). The pre-cleared lysate was  incubated with
anti-GLI1 antibody (Rockland, Gilbertsville, PA) for 1 h and then
with protein G-Plus agarose for 1 h. Immune complexes were col-
lected, washed and Western blot was  performed using anti-TAF9
antibody (Santa Cruz Biotech, Santa Cruz, CA).
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Fig. 1. Interactions of GLI family members with TAF9. A. Variations in the TAD1s of human, mouse, and Drosophila GLI family members compared with that of Herpes simplex
viral  protein VP-16 (shaded yellow). The vertebrate domains include a conserved FXX (where F = phenylalanine, X = any amino acid, and  = any hydrophobic amino acid
doublet) TAF9 binding motif yet demonstrate differences in the amino acids that would putatively directly contact TAF9. *s indicate amino acids that potentially directly
contact TAF9 based on analysis using VP-16. These residues are shaded (green) if they are identical to those found in VP-16 (472D, 479F, and 483L). B. TAD1s of human GLI
family members activate reporter gene transcription to differing degrees in HeLa cells. The amount of GLI effector DNA (ng) is indicated on the x-axis for each construct.
*s  indicate statistically increased luciferase activity (p ≤ 0.05) compared to the baseline established with no GLI DNA. C. GST pull-down assays were conducted using plain
beads  (B), GST coated beads (GST-B) or beads coated with GST-TAF9 (GST-TAF9-B) and either histidine tagged-GLI1 TAD1 (left), -GLI2 TAD1 (middle), or -GLI3 TAD1 (right).
Western blots using an anti-histidine tag antibody on the protein fraction that was  bound to the beads are shown. Bands indicate that GLI1 and GLI2, but not GLI3, were
bound  to the GST-TAF9 beads. A molecular weight size marker (kDa) is shown. D. Co-immunoprecipitation assay was  conducted by immunoprecipitating GLI1 from RMS-13
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.6. Proximity ligation assays (PLA)
PLA was performed as described by the manufacturer (Olink
ioscience, Uppsala, Sweden). RMS-13 cells (ATCC CRL-2061), OsA-
L cells (ATCC CRL-2098) and HepG2 cells (ATCC HB-8065) were
urchased from ATCC (Manassas, VA) and together with anti-GLI1
ntibody (Cell Signaling, Danvers, MA)  and/or anti-TAF9 antibody
ere used for PLA. Fluorescent signals were observed using a
eiss 510 META confocal laser-scanning microscope (Carl Zeiss,
ena, Germany). Three-dimensional (3D) reconstructions of PLA
ata were created using Volocity 3D Image Analysis Software
PerkinElmer, Waltham, MA). Differential Interference Contrast
ata were adjusted in Adobe Photoshop (San Jose, CA) to allow cell
oundary approximations to be visualized in 3D reconstructions.
.7. Cell transformation assaysRK3E cells (ATCC CRL1895, Manassas, VA) were maintained in
MEM (Gibco-BRL, Grand Islands, NY) and transfected with pLTR,
LTR-GLI1 or pLTR-GLI1853-1106. Foci were counted after 2–4d fraction by Western blot. A molecular weight size marker (kDa) is shown.
weeks of incubation. All experiments were performed at least in
triplicate and results expressed as a mean with standard deviation.
Statistical signiﬁcance was assessed using the Student’s t test.
2.8. Treatment of RK3E cells with a proteosome inhibitor
Pact-Flag-GLI3 (obtained from Dr. Ishii, Tsukuba Life Science
Center, Ibaraki, Japan) [14] was  transfected into RK3E cells using
Lipofectamine 2000 reagent. After 48 h, the cells were treated with
50 M MG-115 (Enzo Life Sciences, Farmingdale, NY). Cell lysates
were prepared followed by Western blot using monoclonal anti-
Flag antibody.
2.9. Methylthiazolyl diphenyl-tetrazolium bromide (MTT) cell
viability assaysThe MTT  assay was performed as described with minor mod-
iﬁcations [7]. The experiments were performed in triplicate on
independently derived materials and results expressed as a mean
12 J.W. Yoon et al. / DNA Repair 34 (2015) 9–17
Fig. 2. Interaction of GLI1 and TAF9 in cells. A. PLA using GLI1 alone (left lane), GLI1 + TAF9 (middle lane), or TAF9 alone (right lane) in GLI1-expressing cells (RMS-13 and
OsA-CL) or negative control cells that do not express GLI1 (HepG2), show predominantly intra-nuclear ﬂuorescent signals (red) by confocal laser scanning microscopy in the
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aLI1-expressing cells. DAPI staining (blue) indicates the nuclei. B. Three-dimension
nd  TAF9 most frequently within the nucleus (nuclei shown in blue). Cell boundar
o-antibody control for RMS-13 cells (one antibody control results are similar).
ith standard deviation. Statistical signiﬁcance was  assessed using
he Student’s t test.
.10 Two-hybrid assays
The two-hybrid assay was performed using the mammalian
atchmaker two-hybrid assay kit (Clontech, Mountain View, CA).
eLa cells were co-transfected with pM-p53 (Clontech, Mountain
iew, CA), pVP-16-GLI1, pG5CAT, and the pSV40-GAL reporter.
ell lysates were prepared 48 h after transfection. -galactosidase
ctivity was used to normalize CAT activity.nstruction of PLA data for RMS-13 cells. PLA signal (red) shows interaction of GLI1
wn in gray. The sides of the squares in the mesh measure 10.24 m.  Inset depicts
3. Results
3.1. The transactivation domain of GLI1 is VP-16 like
We  compared the amino acid sequences of TAD1s of GLI fam-
ily proteins with the transactivation domain of the Herpes simplex
viral protein VP-16, which has served as the proto-type for acidic
alpha-helical transactivation domains (Fig. 1A). Since VP-16 binds
TAF9 through an FXX consensus recognition motif and directly
contacts TAF9 at three residues (D472, F479, and L483) [19],
we searched the transactivation domains of human, mouse, and
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Fig. 3. Impact of TAF9 binding on GLI family protein function. A. RK3E cells were transfected with pLTR (negative control), pLTR-GLI1 (positive control), or GLI1 lacking amino
acids  853–1106 (pLTR-GLI1853-1106). The number of foci per 60 mm plate is shown. * indicates a statistically signiﬁcant difference (p = 0.01) between the number of foci
when  RK3E cells were transfected with GLI1 or with GLI1853-1106. B. Cell-free pull-down assays were completed as for Fig. 1C using plain beads (B), beads coated with GST
(GST-B) or beads coated with GST-TAF9 (GST-TAF9-B) and either histidine tagged-GLI1 TAD1 L1052I or -GLI3 TAD1 I1510L. Western blots using an anti-histidine tag antibody
on  the protein fraction that was bound to the beads are shown. Compared with Fig. 1C, GLI1 L1052I abolished the ability of GLI1 to bind TAF9 while GLI3 I1510L established
the  ability to bind TAF9 (arrow) in cell-free assays. Molecular weight size markers (kDa) are shown. C. pM-GLI1 L1052I (white bars) shows decreased transcriptional activity
compared with pM-GLI1 (black bars) in HeLa cells. The amount of pM-GLI1 or pM-GLI1 L1052I is indicated on the x-axis. *s indicate a statistically signiﬁcant reduction
(p  ≤ 0.05) in transcriptional activity when comparing the results for pM-GLI1 with pM-GLI1 L1052I. D. pM-GLI1TAD1 L1052I (white bars) shows decreased transcriptional
activity compared with pM-GLI1TAD1 (black bars) in HeLa cells. The amount of pM-GLI1TAD1 or pM-GLI1TAD1 L1052I is indicated on the x-axis. *s indicate a statistically
signiﬁcant reduction (p ≤ 0.05) in transcriptional activity when comparing the results for pM-GLI1TAD1 with pM-GLI1TAD1 L1052I. E. pM-GLI3TAD1 I1510L (white bars)
shows  enhanced transcriptional activity compared with pM-GLI3TAD1 (black bars). The amount of pM-GLI3TAD1 or pM-GLI3TAD1 I1510L is indicated on the x-axis. *s
indicate  a statistically signiﬁcant increase (p ≤ 0.05) in transcriptional activity when comparing the results for pM-GLI3TAD1 with pM-GLI3TAD1 I1510L. F. Introduction of
the  L1052I point mutation into full length GLI1 decreases GLI1-induced RK3E cell transformation. * indicates a statistically signiﬁcant decrease (p = 0.04) in the number of
foci  when comparing RK3E cells transfected with pLTR-GLI1 with pLTR-GLI1 L1052I. G. Stabilization of Flag-tagged GLI3 protein by the proteosome inhibitor MG-115 in
RK3E  cells. Western blot using an anti-Flag antibody and lysate from RK3E cells transfected with pLTR (negative control), Pact-Flag-GLI3, or Pact-Flag-GLI3 in the presence of
MG-115 shows Flag-tagged GLI3 protein only when the proteosome inhibitor is added. The blot was  stripped and re-probed with anti-GAPDH antibody (Santa Cruz Biotech,
Santa  Cruz, CA) to ensure equal loading. A molecular weight size marker (kDa) is shown.
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Fig. 4. p53 demonstrates greater binding afﬁnity than GLI1 TAD1 for TAF9 in cell-
free assays. A. GST binding assays were conducted as in Fig. 1C, this time between
GST-TAF9 and either GLI1 TAD1 or p53. The amount of either p53 or GLI1 TAD1 that
was  added to the GST-TAF9 beads is indicated on the x-axis. Western blots were con-
ducted on the protein fraction that was  bound to the beads using anti-T7 antibody.
The intensity of the p53 or GLI1 TAD1 bands was  quantitated using Silverfast scan-
ning software. Results are shown in relative units (RU). B. Cell-free binding assay
conducted as in Fig. 1C, this time between GST-TAF9 and the combination of GLI1
TAD1 and p53 added together in varying molar ratios. A Western blot using anti-T7
antibody is shown. Lane 1: p53 alone, Lane 2: GLI1 TAD1 alone, Lane 3: p53:GLI1
TAD1 molar ratio = 0.07, Lane 4: p53:GLI1 TAD1 = 0.31, Lane 5: p53:GLI1 TAD1 = 1.26,4 J.W. Yoon et al. / DN
rosophila GLI family members for these elements in order to assess
heir potential to bind TAF9. Although the FXX recognition motif
as conserved in all of the vertebrate GLI proteins, we  found dif-
erences in the amino acids that would putatively directly contact
AF9. Therefore, we tested the ability of each human GLI family
AD1 to activate transcription and to bind TAF9 in cell-free pull-
own assays.
Fusion proteins, which included TAD1s of different GLI family
embers linked with the GAL4 DNA binding domain, activated
ranscription of a reporter gene to differing degrees in HeLa cells
GLI1 > GLI2 > GLI3) and only the transactivation domains of the
ncogenic family members GLI1 and GLI2 interacted with TAF9
n cell-free pull-down assays (Fig. 1B and C). We  demonstrated
hat GLI1 interacts with TAF9 in rhabdomyosarcoma (RMS-13) cells
y co-immunoprecipitation (Fig. 1D) and in RMS-13 and osteosar-
oma (OsA-CL) cells, both of which express high levels of GLI1, by
LA (Fig. 2). The signals identifying GLI1-TAF9 interactions were
redominately intra-nuclear. Therefore, the oncogenic GLI family
embers GLI1 and GLI2 interact with the coactivator TAF9 while
LI3 does not.
.2. Signiﬁcance of TAF9 binding
To determine the functional signiﬁcance of TAF9 binding, we
emoved the carboxy terminus of the GLI1 protein (amino acids
53–1106), including the previously deﬁned TAD1 (amino acids
020–1091) [16] and tested its ability to transform RK3E cells.
emoval of this region signiﬁcantly reduced the ability of GLI1 to
ransform the cells (Fig. 3A). Next, based on our cell-free binding
ata using wild-type GLI1 and GLI3, we introduced a point mutation
nto the transactivation domain of GLI1 (L1052I) that eliminated
ell-free binding and into the GLI3 domain (I1510L) that established
ell-free binding to TAF9 (Fig. 3B) and assessed transactivating and
ell transforming abilities. Near full length wild-type GLI1 showed
nhanced transactivation compared with GLI1 carrying the L1052I
oint mutation (Fig. 3C). Similarly, wild-type and mutant GLI TAD1s
hat bind TAF9 showed enhanced transactivation compared with
hose that do not bind TAF9 (Fig. 3D, E). Wild-type and mutant
M-GLI1 (Fig. 3C), wild-type and mutant pM-GLI1TAD1 (Fig. 3D)
s well as wild-type and mutant pM-GLI3TAD1 (Fig. 3E) proteins
ere expressed at similar levels by western blot (data not shown).
n addition, transfection of the full length GLI1 L1052I mutant into
K3E cells resulted in signiﬁcantly fewer foci than wild-type GLI1
Fig. 3F). We  were not surprised that focus formation was  not elimi-
ated altogether based on the fact that a single point mutation may
ot entirely abolish TAF9 binding in cells. GLI3 and the GLI3 I1510L
utant protein proved to be unstable in RK3E cells (Fig. 3G).
.3. p53 competes with GLI1 for TAF9 binding
Since TAF9 levels are tightly regulated, it is possible that dif-
erent transcription factors that bind TAF9 compete for limited
mounts of the coactivator and that co-expression of these tran-
cription factors represents a mechanism by which transactivation
nd cell transformation can be modulated [29]. Since the p53 acidic
lpha-helical transactivation domain interacts with TAF9, and p53
as been shown to inhibit GLI1 activity, we tested the relative bind-
ng afﬁnities of GLI1 and p53 in cell-free pull-down assays [18].
sing a ﬁxed amount of TAF9 protein, p53 showed greater TAF9
inding than GLI1 at any given pico-molar amount (Fig. 4A). When
ested for their abilities to directly compete for binding, p53 once
gain demonstrated greater TAF9 binding than GLI1 (Fig. 4B).Lane 6: p53:GLI1 TAD1 = 5.07. The box indicates results using a ratio of p53 to GLI1
TAD1 closest to 1. A molecular weight size marker (kDa) is shown. Extra non-speciﬁc
bands of uncertain signiﬁcance appear at the highest p53 concentrations.
3.4. p53 sequesters TAF9 from GLI
To test whether p53 sequesters TAF9 from GLI1 and GLI2, we
cotransfected p53 into HeLa cells with either wild-type GLI1 TAD1,
the GLI1 TAD1 L1052I mutant, full length GLI1 or full length GLI2
and assessed the effect on GLI-induced transactivation. Transacti-
vation by GLI1 TAD1 was signiﬁcantly reduced, more so than the
GLI1 TAD1 L1052I mutant (Fig. 5A). The fact that some reduction in
transactivation was  seen for GLI1 TAD1 L1052I suggests that TAF9
binding is not abolished completely in cells by the point mutation
or that p53 may  exert effects on GLI1 transactivation other than by
competition for TAF9. Transactivation by full length GLI1 and GLI2
were also signiﬁcantly reduced in the presence of p53 (Fig. 5B).
GLI3 TAD1 on the other hand demonstrated very low transacti-
vating activity, and therefore the effect of p53 on transactivation
by GLI3 TAD1 could not be determined. Down-regulation of GLI1
TAD1-induced transactivation by p53 did not occur using 10 or 30
ng of a p53 mutant (p53 22-23) that does not bind TAF9, supporting
the importance of p53-TAF9 interactions in down-regulating GLI1-
induced transactivation (Fig. 5C). At 100 ng of p53 22–23 mutant
DNA, GLI1-induced transactivation was reduced although the bio-
logic signiﬁcance is uncertain. Naturally occurring p53 mutants
that carry point mutations at hotspots outside of the TAF9 binding
domain (p53 R175H and p53 R248W), reduced GLI1 activity, but
to a lesser degree than wild type p53. This may  be due to reduced
afﬁnity of mutant p53 for TAF9 or to other mechanisms that may
not involve TAF9 [17]. Cell viability assays showed no signiﬁcant
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Fig. 5. p53 reduces GLI-induced transcriptional activity by sequestering their shared coactivator TAF9. A. GLI1 TAD1-induced transactivation was assessed in HeLa cells
transfected with 50 ng pM-GLI1TAD1 + p53 (pRc/CMVhp53) + 200 ng pG5Luc (black bars), 50 ng pM-GLI1TAD1 L1052I + p53 (pRc/CMVhp53) + 200 ng pG5Luc (white bars),
or  50 ng pM-GLI1TAD1 + pBluescript DNA + 200 ng pG5Luc (gray bars). The amount of p53 vector or pBluescript (ng) is indicated on the x-axis. *s indicate a statistically
signiﬁcant decrease in GLI1 TAD1 activity (p ≤ 0.05) between 0 ng p53 and either 20 ng or 100 ng p53. **s indicate a statistically signiﬁcant (p ≤ 0.05) reduction in GLI1-
induced  transactivation for GLI1 compared with GLI1 L1052I. B. Transactivation by full length GLI1 or GLI2 was assessed in HeLa cells transfected with 125 ng pCMV-GLI1
(left  panel) or pCMV-GLI2 (right panel) + p53 (pRc/CMVhp53) + 200 ng pGL3b/8XGli-lc-luc (black bars) or 125 ng of pcDNA3 (both panels) + p53 (pRc/CMVhp53) + 200 ng
pGL3b/8XgGli-lc-luc (white bars). The amount of p53 (ng) is indicated on the x-axis. *s indicate a statistically signiﬁcant decrease in GLI1 or GLI2 activity (p ≤ 0.05) between
0  ng p53 and either 20 ng or 100 ng p53. C. GLI1-induced transactivation was  assessed in HeLa cells transfected with 125 ng pM-GLI1TAD1 + p53 (pRc/CMVhp53) + 200 ng
pG5Luc (black bars), 125 ng pM-GLI1TAD1 + pcDNA3 + 200 ng pG5Luc (vertical striped bars), or 125 ng pM-GLI1TAD1 + p53 R175H mutant + 200 ng pG5Luc (horizontal striped
bars),  or 125 ng pM-GLI1TAD1 + p53 R248W mutant + 200 ng pG5Luc (diagonal striped bars), or 125 ng pM-GLI1TAD1 + p53 22–23 mutant + 200 ng pG5Luc (white bars). The
amount  of p53 (wild-type or mutant) or control DNA (pcDNA3) (ng) is indicated on the x-axis. *s indicate a statistically signiﬁcant decrease in GLI1 TAD1 activity (p ≤ 0.05)
between 0 ng pRc/CMVhp53 and either 10, 20 ng or 100 ng pRc/CMVhp53, p53 R175H mutant or p53 R248W mutant. D. MTT  cell viability assays were conducted using HeLa
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eduction following transfection of GLI1 TAD1 with either the wild-
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own-regulation of GLI1 TAD1-induced transactivation by p53 is
ot a result of cell loss (Fig. 5D). We  did not try to abrogate the
ffect of GLI1 on RK3E cell transformation by co-transfection of p53
r p53 mutants, because we could not conclude that any reduction
n cell transformation was only a result of TAF9 sequestration by
53.
.5. p53 does not bind GLI1 directlyIf p53 binds TAF9 with higher afﬁnity than GLI1 binds TAF9,
hen we would not expect GLI1 to down-regulate transactivation
y p53. Indeed, GLI1 did not down-regulate p53-induced trans-
ctivation in p53 (−/−) mouse embryonic ﬁbroblasts (MEF cells)), or the p53 22–23 mutant (white bars). The amount of p53 (pRc/CMVhp53 or p53
xis. Neither the wild-type nor mutant p53 DNA caused a reduction in cell viability
or HeLa cells (data not shown). Finally, we assessed whether p53
might interfere with the GLI1-TAF9 interaction by directly interact-
ing with GLI1. We  did not ﬁnd evidence that p53 directly interacts
with GLI1 using the two-hybrid assay (data not shown). Together,
our results demonstrate that GLI1-induced transactivation can be
down-regulated by p53 based on sequestration of their shared
coactivator TAF9.
4. Discussion
We show that TAF9 binds TAD1 domains of the oncogenic GLI
family members GLI1 and GLI2 but not GLI3. We demonstrate
physiologic relevance of these ﬁndings by showing interactions
between GLI1 and TAF9 in unmanipulated human rhabdomyosar-
coma and osteosarcoma cells. In cell-free assays TAF9 binding can
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amily TAD1 domains and full length proteins that bind TAF9 show
nhanced transactivation and cell transformation compared with
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In addition, we demonstrate that p53 binds TAF9 with greater
fﬁnity in cell-free assays than GLI1 TAD1 binds TAF9. We  show
hat p53 inhibits transactivation by GLI1 and GLI2. This effect can
e reduced using the GLI1 L1052I mutant, which does not bind TAF9
n cell-free assays, or a mutant form of p53, which does not bind
AF9. This suggests that p53 can sequester TAF9 from GLI1 in cells
nd thereby inhibit transactivation by GLI1. Taken together, these
ata suggest that the interaction of GLI family transcription factors
ith the coactivator TAF9 is associated with enhanced transactiva-
ion and cell transformation and may  be modulated by p53. TAF9
inding may  represent an essential element for oncogenic activity
y this family of transcription factors.
A subset of transcription factors with acidic alpha helical-type
ransactivation domains interacts with TAF9, including VP-16 and
53 [19,20]. TAF9 is a component of TFIID and the human histone-
cetylase complex, suggesting roles for TAF9 in the regulation of
ene transcription both at the level of RNA polymerase recruitment
nd chromatin modiﬁcation [30–32]. Although GLI family tran-
cription factors share a highly conserved zinc ﬁnger DNA binding
omain with presumed binding speciﬁcity, target gene regulation
nd therefore cellular consequences could differ based on TAF9
inding. Others have raised the possibility that TAF9 contributes to
 pattern of gene regulation that at least under some circumstances
an contribute to cell cycle progression, cell survival, or transfor-
ation [20,33–37]. The fact that TAF9 interacts with GLI1 and GLI2,
ut not GLI3 suggests a potential role for TAF9 in GLI family-induced
ncogenesis that likely involves regulation of a speciﬁc pattern of
arget genes.
We propose a mechanism for modulation of GLI1-TAF9 interac-
ions whereby limiting amounts of cellular TAF9 can be sequestered
y p53, which binds TAF9 with greater afﬁnity than GLI1 binds
AF9. Since the amount of TAF9 is tightly controlled in the cell [27],
his suggests that a change in the balance of GLI1 and p53 may
ffect transactivation by GLI1 and therefore cellular phenotype.
ndeed, the concept of sequestration of a coactivator by compe-
ition among different proteins that can bind to the coactivator has
een previously described [27,38–43].
We  previously showed that p53 is an indirect target of GLI1 in
ransformed RK3E cells and a similar expression pattern was  seen
n desmoplastic medulloblastoma [44]. The reported mechanism
or the GLI1-p53 inhibitory loop that controls neural stem cell and
umor cell numbers includes inhibition of GLI1 activity, nuclear
ocalization of GLI1, and alterations in phosphorylation of the N’
soform of GLI1 [18]. Our data raise the possibility that seques-
ration of TAF9 could play a role in this feed back loop and that
ysregulation could occur in cancer. Our experiments have only
een conducted in tumor cell lines with activated p53. Sequestra-
ion of TAF9 remains to be shown with basal levels of p53 during
evelopment.
Although mutations in the acidic alpha helical transactivation
omain of p53, which would directly interfere with p53-TAF9
nteractions, are unusual in human cancer, it is possible that p53
utations in other regions of the protein may  alter protein con-
guration and affect the ability of the amino terminal region of
53 to interact with TAF9. Our results with p53 R175H and R248W
utants suggest that this may  occur. Interactions of mutant forms
f p53 with TAF9 have not been systematically tested. It is also
ossible that MDM2  up-regulation in cancer cells that express p53
nd GLI1 can enhance the availability of TAF9 for GLI1 since MDM2
nhibits the interaction of p53 with TAF9 through a p53-speciﬁc
otif (P19, L22, W23) [20,45–51]. Co-expression of other tran-
[air 34 (2015) 9–17
scription factors that bind TAF9 could also compete for TAF9 and
potentially modify the function of their competitors during devel-
opment or in cancer. Moreover, GLI1 has been shown to depress
mismatch repair [52] and the possible signiﬁcance of that in the
context of p53 activity has been discussed [43]. Understanding the
role of speciﬁc elements of the transcriptional machinery and the
signiﬁcance of interactions between these elements will be key to
not only understanding oncogenesis but to developing new thera-
peutic strategies.
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